Great experiment! It’s important to highlight that even in rigorously blinded studies which find a drug ineffective on average, there can still be genuine responders—this is known scientifically as “heterogeneous treatment effects.” Essentially, individuals vary in genetics, metabolism, and neurochemistry, which can cause meaningful differences in drug responsiveness. Thus, an N=1 trial, like yours, might indeed reveal real personal benefits that wouldn’t appear in a population-level analysis.

However, systematically performing robust N=1 trials individually across multiple substances can be impractical—too laborious and time-consuming for most people. An interesting business model might be a startup that facilitates personalized N=1 experiments at scale: providing users with high-quality compounds, matched placebos, structured dosing schedules, and data-tracking tools. This could empower more individuals to accurately assess personal efficacy across a wide variety of substances, potentially offering valuable, personalized insights that large-scale clinical trials can’t capture.